Brain metastasis

GT Medical Technologies, Inc. Presents Use of GammaTile Therapy is Increasing in Time Across Several Brain Tumor Types at the 28th Annual Scientific Meeting and Education Day at the Society of Neuro-Oncology (SNO)

Retrieved on: 
Friday, November 17, 2023
Quality, Education, Radiation, Treatment, Brain metastasis, Seed, Glioblastoma, Brain, Convention, Patient, Abstract, Caesium, Pakistan Society of Neuro-Oncology, FDA, Quality of life, Meningioma, BED, Neuro, Cancer, Metastasis, Radiosurgery, Doctor of Philosophy, Neoplasm, Use, Society, Poster, SNO, Medical physics, Medical imaging, Glioma

TEMPE, Ariz., Nov. 17, 2023 /PRNewswire/ -- GT Medical Technologies, Inc., a medical device company dedicated to improving the lives of patients with brain tumors, today announced an increase of clinical cases in the United States using its GammaTile® Therapy in patients diagnosed with several brain tumor types. The data was presented at the Society for Neuro-Oncology (SNO) 28th Annual Meeting and Education Day taking place from November 15-19, 2023, at the Vancouver Convention Center in Vancouver, Canada.

Key Points: 
  • The data was presented at the Society for Neuro-Oncology (SNO) 28th Annual Meeting and Education Day taking place from November 15-19, 2023, at the Vancouver Convention Center in Vancouver, Canada.
  • GammaTile has been used in over 1,000 patients with both newly diagnosed malignant brain tumors and recurrent brain tumors since 2019 and has been used in different tumor types, including glioblastoma, brain metastasis and meningioma.
  • Currently, GammaTile is sponsoring 4 clinical trials including a multi-institute registry trial (NCT0442738) that includes quality of life as a study metric.
  • GammaTile Therapy is a Surgically Targeted Radiation Therapy (STaRT) that delivers immediate radiation and eradicates brain tumor cells before they can replicate post-surgery while helping to protect healthy brain tissue.

Patrys Limited Announces Publication of PAT-DX1 Preclinical Data in JCI - Insight

Retrieved on: 
Wednesday, June 16, 2021
Research, Publishing, Genetics, Clinical trials, Communications, Biotechnology, Pharmaceutical, Health, Science, Oncology, Brain tumor, Aging-associated diseases, Cancer, Health, Clinical medicine, Oncology, Brain metastasis, Blastoma, Glioblastoma

Patrys Limited (ASX:PAB), a therapeutic antibody development company, has announced the publication of preclinical data for its therapeutic antibody candidate PAT-DX1 in The Journal of Clinical InvestigationInsight.

Key Points: 
  • Patrys Limited (ASX:PAB), a therapeutic antibody development company, has announced the publication of preclinical data for its therapeutic antibody candidate PAT-DX1 in The Journal of Clinical InvestigationInsight.
  • Patrys is developing PAT-DX1 for use in DDR-deficient cancers, including a range of primary brain cancers and metastases.
  • Glioblastoma and TNBC brain metastases are very difficult to treat, and the prognosis for patients with these cancers is generally poor.
  • For more information about Patrys, please visit www.patrys.com and follow us on Twitter (@PatrysLtd) and LinkedIn.

Spectrum Pharmaceuticals Presents Poziotinib Data in Patients with Brain Metastases from the ZENITH20 Clinical Trial at 2021 ASCO Annual Meeting

Retrieved on: 
Friday, June 4, 2021
Biotechnology, Pharmaceutical, Health, Clinical trials, Lung cancer, Tyrosine kinase receptors, Cancer treatments, Non-small-cell lung carcinoma, Clinical medicine, Brain metastasis, HER2/neu, Cancer, Medicine

These data from Cohorts 1, 2 and 3 of the ongoing ZENITH20 clinical trial assessed the results from 36 patients with brain metastases at baseline with three patients (8%) achieving intracranial complete responses.

Key Points: 
  • These data from Cohorts 1, 2 and 3 of the ongoing ZENITH20 clinical trial assessed the results from 36 patients with brain metastases at baseline with three patients (8%) achieving intracranial complete responses.
  • The presentation titled CNS activity of poziotinib in NSCLC with exon 20 insertion mutations is available on the website for the 2021 ASCO Annual Meeting being held June 4-8, 2021.
  • CNS metastases are a common and life-threatening complication of metastatic disease in NSCLC patients, said Francois Lebel, M.D., Chief Medical Officer of Spectrum Pharmaceuticals.
  • These data show clinically meaningful CNS activity for poziotinib treated NSCLC patients with CNS metastases with EGFR or HER2 exon 20 insertion mutations.

NhTherAguix: NH TherAguix and the CHU Grenoble-Alpes announce the publication of the results of the First-In-Human phase 1 clinical trial on the combination of AGuIX with radiotherapy

Retrieved on: 
Monday, May 31, 2021
Medicine, Clinical medicine, Medical physics, Radiobiology, Brain tumor, Radiation therapy, Radioactivity, Brain metastasis, Prophylactic cranial irradiation, Limited-stage small cell lung carcinoma

NH TherAguix and the CHU Grenoble-Alpes announce the publication of the results of the First-In-Human phase 1 clinical trial on the combination of AGuIX with radiotherapy on multiple brain metastases patients.

Key Points: 
  • NH TherAguix and the CHU Grenoble-Alpes announce the publication of the results of the First-In-Human phase 1 clinical trial on the combination of AGuIX with radiotherapy on multiple brain metastases patients.
  • All patients have received one intravenous injection of AGuIX associated with a conventional whole brain radiation therapy (10 x 3 Gy).
  • This trial has demonstrated that the combination of AGuIX with radiotherapy for these patients is safe and feasible.
  • Thus, the dose of 100 mg/kg, reached without occurrence of dose limiting toxicities, was selected for the phase II trial that is currently ongoing.

Zai Lab Announces First Patient Treated in Greater China in METIS Phase 3 Pivotal Trial of Tumor Treating Fields in Brain Metastases from Non-Small Cell Lung Cancer

Retrieved on: 
Monday, May 24, 2021
Lung cancer, Clinical medicine, Medicine, Cancer, Non-small-cell lung carcinoma, Brain metastasis, Small-cell carcinoma, Treatment of lung cancer, Targeted therapy of lung cancer

Patients with brain metastasis resulting from non-small cell lung cancer generally have few treatment options and poor outcomes.

Key Points: 
  • Patients with brain metastasis resulting from non-small cell lung cancer generally have few treatment options and poor outcomes.
  • We look forward to generating data from use of Tumor Treating Fields in this and several other major cancer types as soon as possible.
  • TTFields are administered to patients concomitantly with the best standard of care treatments that would normally be used to treat lung cancer.
  • Lung cancer consists of NSCLC in approximately 85% of cases and small cell lung cancer (SCLC) in approximately 15% of cases.

Global Brain Cancer Markets, Epidemiology and Patient Flow Analysis Report 2020-2035 - ResearchAndMarkets.com

Retrieved on: 
Friday, May 14, 2021
Pharmaceutical, Health, Oncology, Cancer, Carcinogenesis, Epidemiology of cancer, Brain tumor, Health, Medicine, Oncology, Brain metastasis

b'The "Global Brain Cancer Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Brain Cancer Epidemiology and Patient Flow Analysis - 2021, provides Brain Cancer epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Brain Cancer Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Brain Cancer Epidemiology and Patient Flow Analysis - 2021, provides Brain Cancer epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Brain Cancer patients, history of the disease at the population level (Brain Cancer prevalence, Brain Cancer incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nDemographics: Brain Cancer patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Brain Cancer market sizing, assessing market potential, and developing drug forecast models\nIdentify Brain Cancer patients segments through age groups, gender, and disease sub-types\nEvaluate Brain Cancer market opportunities, identify target patient population\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210514005195/en/\n'

Ashvattha Therapeutics to Present at 2021 Sachs 7th Annual Digital Immuno-Oncology Innovation Forum

Retrieved on: 
Tuesday, May 11, 2021
Biotechnology, Pharmaceutical, Health, Clinical trials, Brain tumor, Dendrimer, Brain metastasis, Glioma

We are developing an HD imaging agent, D6-B483, to demonstrate uptake of HDs in gliomas and brain metastases.

Key Points: 
  • We are developing an HD imaging agent, D6-B483, to demonstrate uptake of HDs in gliomas and brain metastases.
  • Current cancer treatments have dose-limiting toxicity reducing efficacy, and even precision medicine and targeted therapies lack sufficient specificity to tumors.
  • Its proprietary compounds also target and treat brain tumors with durable effects inside TAMs for up to 30 days.
  • Ashvattha are commercializing the technology through new entities established to develop therapeutic opportunities within specific fields and enabled through the use of our dendrimer platform.

Novocure Announces FDA IDE Approval and Steering Committee for KEYNOTE-B36 Trial Evaluating Tumor Treating Fields Together with Pembrolizumab in Non-Small Cell Lung Cancer

Retrieved on: 
Thursday, April 22, 2021
Oncology, FDA, Health, Clinical trials, Pharmaceutical, Biotechnology, Clinical medicine, Cancer treatments, Medicine, Breakthrough therapy, Orphan drugs, Antineoplastic drugs, Lung cancer, Cancer immunotherapy, Pembrolizumab, Non-small-cell lung carcinoma, Brain metastasis, Cancer, KEYNOTE-B36, Non-small Cell Lung Cancer, Tumor Treating Fields, Novocure, KEYNOTE-B36, NON-SMALL CELL LUNG CANCER, TUMOR TREATING FIELDS, NOVOCURE

KEYNOTE-B36 will evaluate the effectiveness of TTFields together with pembrolizumab for first-line treatment of locally advanced or metastatic intrathoracic, PD-L1 positive NSCLC.

Key Points: 
  • KEYNOTE-B36 will evaluate the effectiveness of TTFields together with pembrolizumab for first-line treatment of locally advanced or metastatic intrathoracic, PD-L1 positive NSCLC.
  • Electrically charged proteins within the cell are critical for cell division, making the rapidly dividing cancer cells vulnerable to electrical interference.
  • Tumor Treating Fields are electric fields that disrupt cancer cell division.
  • Novocure has ongoing clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.\nHeadquartered in Jersey, Novocure has U.S. operations in Portsmouth, New Hampshire, Malvern, Pennsylvania and New York City.

ZAP Surgical Announces Future Installation of Novel Non-Invasive Brain Tumor Treatment System in Munich, Germany

Retrieved on: 
Tuesday, April 20, 2021
Oncology, Health, Hospitals, Surgery, Pharmaceutical, Biotechnology, Clinical medicine, Medicine, Neurosurgery, Medical specialties, Radiosurgery, Cyberknife, Brain tumor, ZAP, Brain metastasis, XC2, ZAP, ZAP Surgical Systems, Inc., European CyberKnife Center Munich, ZAP SURGICAL SYSTEMS, INC., EUROPEAN CYBERKNIFE CENTER MUNICH

b"ZAP Surgical Systems, Inc. today announced the upcoming installation of its advanced ZAP-X\xc2\xae Gyroscopic Radiosurgery\xc2\xae platform at the European CyberKnife\xc2\xae Center in Munich, Germany.

Key Points: 
  • b"ZAP Surgical Systems, Inc. today announced the upcoming installation of its advanced ZAP-X\xc2\xae Gyroscopic Radiosurgery\xc2\xae platform at the European CyberKnife\xc2\xae Center in Munich, Germany.
  • Having recently received CE-clearance for clinical use in Europe, the installation will be among the first ZAP-X systems in the world.
  • View the full release here: https://www.businesswire.com/news/home/20210420005003/en/\nZAP-X Gyroscopic Radiosurgery Platform (Photo: Business Wire)\nAs a non-invasive treatment for select brain tumors and brain metastases, SRS is a well-studied and proven procedure that often provides equivalent or superior outcomes to surgery.
  • The ZAP-X platform incorporates a unique vault-free design that typically eliminates the need for costly shielded treatment rooms.

Novocure Announces 26 Presentations at American Association for Cancer Research (AACR) Annual Meeting 2021 Suggesting Broad Applicability of Tumor Treating Fields

Retrieved on: 
Friday, April 9, 2021
Oncology, Medical devices, Health, Other Health, Radiology, Biotechnology, Cancer, Clinical medicine, Medicine, Oncology, Cancer treatments, Gynaecological cancer, Cancer pathology, Metástasis, Alternating electric field therapy, Brain metastasis, Chemotherapy, Ovarian cancer

Novocure (NASDAQ: NVCR) today announced 26 presentations on Tumor Treating Fields suggesting broad applicability of Tumor Treating Fields at the American Association for Cancer Research (AACR) Annual Meeting 2021, held virtually from April 10 to April 15, 2021.

Key Points: 
  • Novocure (NASDAQ: NVCR) today announced 26 presentations on Tumor Treating Fields suggesting broad applicability of Tumor Treating Fields at the American Association for Cancer Research (AACR) Annual Meeting 2021, held virtually from April 10 to April 15, 2021.
  • Research spanning seven solid tumor types confirms the anti-mitotic effect of Tumor Treating Fields and further explores downstream effects to identify optimal use of Tumor Treating Fields, including the role of Tumor Treating Fields-induced immunogenic cell death.
  • H. Ben Atya (Tumor Biology)
    (Poster #: 3071) A method for infratentorial structures segmentation for tumor treating fields treatment planning.
  • Novocure has ongoing clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.